Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has provided an update.
Cantargia AB has announced successful Phase 1 results for its CAN10 antibody, confirming a 4-week dosing regimen for Phase 2 trials. The study demonstrated high bioavailability and potent, long-lasting inhibitory effects on key inflammatory biomarkers, suggesting significant potential in treating inflammatory diseases such as hidradenitis suppurativa and atopic dermatitis. The results position CAN10 competitively in the market, with plans for Phase 2 studies by the end of 2025, including a randomized study in hidradenitis suppurativa and a pilot study in atopic dermatitis patients unresponsive to existing treatments.
More about Cantargia AB
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program focuses on the antibody nadunolimab (CAN04) in combination with chemotherapy for cancers like pancreatic, non-small cell lung, and triple-negative breast cancer. Their second development program, CAN10, targets serious autoimmune and inflammatory diseases, initially focusing on hidradenitis suppurativa and systemic sclerosis.
YTD Price Performance: -3.55%
Average Trading Volume: 905,409
Current Market Cap: SEK405.2M
For an in-depth examination of CANTA stock, go to TipRanks’ Stock Analysis page.